SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carboplatin
/ administration & dosage
Carcinoma, Transitional Cell
/ drug therapy
Cisplatin
/ administration & dosage
Deoxycytidine
/ administration & dosage
Doxorubicin
/ therapeutic use
Humans
Liver Neoplasms
/ drug therapy
Methotrexate
/ therapeutic use
Nivolumab
/ therapeutic use
Paclitaxel
/ administration & dosage
Urinary Bladder Neoplasms
/ drug therapy
Vinblastine
/ therapeutic use
Gemcitabine
Bladder cancer
Checkpoint inhibitors
Chemotherapy immunotherapy
Urothelial cancer
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
06
08
2018
accepted:
10
09
2018
pubmed:
22
9
2018
medline:
23
5
2019
entrez:
22
9
2018
Statut:
ppublish
Résumé
The SIU (Société Internationale d'Urologie)-ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.
Identifiants
pubmed: 30238401
doi: 10.1007/s00345-018-2486-1
pii: 10.1007/s00345-018-2486-1
pmc: PMC7515768
mid: NIHMS1628286
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Deoxycytidine
0W860991D6
durvalumab
28X28X9OKV
Nivolumab
31YO63LBSN
atezolizumab
52CMI0WC3Y
Vinblastine
5V9KLZ54CY
Doxorubicin
80168379AG
Carboplatin
BG3F62OND5
pembrolizumab
DPT0O3T46P
avelumab
KXG2PJ551I
Paclitaxel
P88XT4IS4D
Cisplatin
Q20Q21Q62J
Methotrexate
YL5FZ2Y5U1
Gemcitabine
0
Types de publication
Journal Article
Practice Guideline
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-105Subventions
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Références
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
J Clin Oncol. 2001 May 15;19(10):2638-46
pubmed: 11352955
Cancer. 2001 Dec 15;92(12):2993-8
pubmed: 11753976
Ann Oncol. 2001 Oct;12(10):1417-22
pubmed: 11762814
J Clin Oncol. 2002 Feb 15;20(4):937-40
pubmed: 11844814
Onkologie. 2002 Feb;25(1):47-52
pubmed: 11893883
J Clin Oncol. 2002 Jul 1;20(13):2965-70
pubmed: 12089226
Cancer. 2005 Jun 1;103(11):2298-303
pubmed: 15856431
Urol Oncol. 2005 May-Jun;23(3):150-4
pubmed: 15907713
J Clin Oncol. 1992 Jul;10(7):1066-73
pubmed: 1607913
Cancer. 2005 Oct 15;104(8):1627-32
pubmed: 16138364
Br J Cancer. 2006 May 22;94(10):1395-401
pubmed: 16622447
Cancer. 2006 Aug 1;107(3):506-13
pubmed: 16773629
J Clin Oncol. 2006 Jul 20;24(21):3451-7
pubmed: 16849761
Ann Oncol. 2006 Oct;17(10):1533-8
pubmed: 16873433
Invest New Drugs. 2007 Jun;25(3):265-70
pubmed: 17146733
Cancer. 2007 Aug 15;110(4):759-63
pubmed: 17594721
Cancer. 2008 Jun 15;112(12):2671-5
pubmed: 18459175
Clin Genitourin Cancer. 2008 Mar;6(1):36-9
pubmed: 18501081
Cancer. 2009 Sep 15;115(18):4090-5
pubmed: 19536901
Cancer. 2009 Sep 15;115(18):4110-7
pubmed: 19536904
J Clin Oncol. 2009 Sep 20;27(27):4454-61
pubmed: 19687335
J Clin Oncol. 2010 Mar 10;28(8):1373-9
pubmed: 20142593
Ann Oncol. 2011 Feb;22(2):288-94
pubmed: 20682548
Int J Clin Oncol. 2011 Aug;16(4):345-51
pubmed: 21331770
J Clin Oncol. 2012 Jan 10;30(2):191-9
pubmed: 22162575
J Clin Oncol. 2012 Apr 1;30(10):1107-13
pubmed: 22370319
Lancet Oncol. 2012 Aug;13(8):810-6
pubmed: 22819172
Clin Genitourin Cancer. 2013 Dec;11(4):477-83
pubmed: 23891158
J Clin Oncol. 2014 Jun 20;32(18):1895-901
pubmed: 24821881
J Clin Oncol. 2014 Jun 20;32(18):1889-94
pubmed: 24821883
Cancer Res Treat. 2014 Apr;46(2):172-7
pubmed: 24851109
Eur Urol. 2015 Apr;67(4):599-602
pubmed: 25465968
Cancer Manag Res. 2015 Jan 19;7:47-50
pubmed: 25632239
Eur Urol. 2016 Apr;69(4):634-641
pubmed: 26264159
Eur Urol. 2016 May;69(5):855-62
pubmed: 26343003
J Urol. 2016 Feb;195(2):254-63
pubmed: 26410730
Ann Oncol. 2016 Jan;27(1):49-61
pubmed: 26487582
J Clin Oncol. 2016 May 1;34(13):1500-9
pubmed: 26926681
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
BMJ Case Rep. 2016 Sep 22;2016:
pubmed: 27659911
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Cancer. 1989 Dec 15;64(12):2448-58
pubmed: 2819654
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
Lancet Oncol. 2017 May;18(5):672-681a
pubmed: 28389316
J Clin Oncol. 2017 Jun 1;35(16):1770-1777
pubmed: 28402747
Eur Urol. 2017 Oct;72(4):477-481
pubmed: 28413128
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
Lancet. 2017 Nov 18;390(10109):2266-2277
pubmed: 28916371
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Lancet. 2018 Feb 24;391(10122):748-757
pubmed: 29268948
Ann Oncol. 1993 Nov;4(9):793-4
pubmed: 8280662
J Clin Oncol. 1997 Feb;15(2):589-93
pubmed: 9053481
J Clin Oncol. 1997 May;15(5):1853-7
pubmed: 9164195
Invest New Drugs. 1998;16(2):191-5
pubmed: 9848585
Eur J Cancer. 1998 Jul;34(8):1208-12
pubmed: 9849481